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High expression of the proprotein processing enzyme FURIN has been associated with tumor progression and metastasis. A SNP
(rs4932178) in the promoter of FURIN has been reported to affect expression in liver, with the T allele resulting in higher expression
than theC allele. In this studywe have investigated the association of this SNPwith prognostic and biological subgroups of colorectal
cancer (CRC). In a panel of 1382 patients with CRC, this SNP had no impact on overall survival or on postoperative risk of relapse.
This SNP also could not be linkedwith FURIN expression levels in CRC samples from the patients. Furthermore, we demonstrate in
luciferase reporter experiments in the colon cancer cell lines Caco-2 and SW480 and in the hepatocellular carcinoma cell line Huh
7 that expression is not affected by the SNP. Since, FURIN inhibition in human colon cancer cell lines has previously been shown
to repress tumor metastases, association between FURIN gene expression levels and postoperative relapse-free survival was also
investigated. However, no association could be found. Altogether, we could not confirm an effect of the SNP on FURIN expression
in vitro and no correlations could be found in vivo with FURIN expression or outcome.
1. Introduction
Colorectal cancer (CRC) ranks second to lung cancer in
both incidence and mortality in developed countries [1]. The
identification and validation of new therapeutic targets to
combat this disease are therefore of the utmost importance.
This goal is, however, complicated by the fact that CRC
is a very heterogeneous disease, where clinicopathological
seemingly similar tumors behave very different in terms
of treatment response and patient survival. Therefore, a
therapeutic strategy with a broad effect that is not restricted
to a single pathway has a higher potential to be successful.
The proprotein convertase Furin was shown to be involved
in many cancer types. Genetic ablation of Furin in a mouse
model for salivary gland tumors significantly delayed the
tumor formation [2], while transgenic mice overexpressing
Furin in the epidermis show enhanced skin cancer devel-
opment [3]. Furin downregulation in colon carcinoma cell
lines inhibited the processing of IGF1R and reduced liver
metastases after injection into the portal vein of mice [4].
Targeting Furin might be a potential therapeutic strategy
affecting multiple pathways simultaneously. Furthermore,
recently the first specific FURIN inhibitors were generated [5]
and now need to be validated in therapeutic applications.
Furin is an endoprotease that cleaves carboxyterminal of
specific basic amino acid motifs and thus activates a variety
of precursor proteins [6, 7]. These precursor proteins include
growth factors and differentiation factors, receptors, adhe-
sion molecules, and enzymes like metalloproteases (MMPs).
These factors play important roles at different stages of tumor
development, progression, vascularization, and metastasis.
Therefore, it is not surprising that FURIN is highly expressed
in various tumor cell lines and human primary tumors [8].
Furthermore, it has been shown that inhibition, knockdown,
and genetic ablation of FURIN reduce tumorigenesis in var-
ious human cancer cells [4]. For example, FURIN inhibition
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in squamous cell carcinoma cell lines resulted in a decreased
proliferation, reduced the anchorage-independent growth in
soft agar assays, and inhibited the in vivo tumorigenicity and
invasion in nudemice [9]. In contrast, FURINoverexpression
in these cell lines resulted in the opposite phenotype and
increased the proliferation and invasiveness [10]. This is also
the case in mice. Transgenic mice, overexpressing Furin,
display enhanced skin tumor formation [3]. Likewise, we
previously demonstrated that genetic ablation of Furin in the
salivary glands inhibited the development and progression
of PLAG1-induced pleomorphic adenomas of the salivary
glands [2]. Inactivation of only a single Furin allele already
resulted in a significantly delayed onset of tumorigenesis.
This suggests that therapeutic benefit can be achieved even
with partial inhibition. PLAG1-induced tumors utilize the
Igf1-receptor (Igf1r) pathway, which is relevant not only in
salivary gland tumors but also in several other types of cancer
including CRCs [11–15]. Studies in CRC cell lines suggest that
FURIN inhibition can repress the metastatic potential [4].
This suppressive effect is mediated via the inhibition of IGF1R
processing. As a result, IGF1-induced AKT phosphorylation,
an important step in colon carcinoma metastasis, is lost.
The expression of FURIN is regulated by three different
promoters, resulting in three distinctFURINmRNA isoforms
which differ only in their 5󸀠-untranslated regions [16]. Pro-
moter P1 contains a TATA box, is transactivated by C/EBP𝛽,
the transcription factor SP1 [16], hypoxia-inducible factor-1
[17], SMAD2/SMAD4 [18], and Gata-1 [19], among others.
The other two promoters (P1A and P1B) lack TATA or CAAT
boxes and contain architectural features of housekeeping
promoters.
A SNP (rs4932178) in the P1 promoter of the FURIN
gene has been reported to affect the expression levels of
FURIN about 3-fold (T allele higher than the C allele) in
HepG2 and HuH7 cell lines [20]. Individuals carrying T
allele were more likely to become persistently infected with
hepatitis B virus infection. This virus requires FURIN for
HBeAg maturation and hence immune response evasion.
This SNP has also been analyzed in a group of 299 patients
withCRC [21]. In this study, the carriers of theCTgenotype of
FURIN C-229T had a worse relapse-free and overall survival
than the carriers of the CC genotype. However, no effect on
survival was observed for the rare TT genotype, diminishing
the value of this finding. Therefore, those studies should
be validated in larger, independent studies. Whether or not
FURIN expression (independently of the SNP) can be linked
with aworse survival probability of patients withCRChas not
been investigated yet.
In this study, the postoperative relapse-free survival
and the survival time of large panel of patients with CRC
have been investigated in correlation with SNP C-229T and
expression of FURIN. Furthermore, the effect of this SNP on
expression of FURIN in CRC cell lines was determined.
2. Materials and Methods
2.1. Patients Characteristics. The trial was a nonblinded
multicenter randomized phase III study conducted within
the Pan-European Trial in Adjuvant Colon Cancer network
as described previously [22]. A total of 1382 patients with
stages II to III adenocarcinoma of the colon were selected.
All patients were between 18 and 75 years old.The aim of this
trial was to assess whether the addition of irinotecan to de
Gramont infusional fluorouracil/leucovorin would improve
disease-free survival (DFS) in patients with stage III colon
cancer. Trial design and the identification of several prognos-
tic markers based on the trial data were reported previously
[23–28].The trial was conducted according to theDeclaration
of Helsinki and its conduction was monitored by a steering
committee and an independent data monitoring committee.
2.2. SNP Analysis. Multiplex PCR was performed in a 5𝜇L
volume containing MegaMix Gold (Cambio), 5–10 ng of
genomic DNA, and 100 nM of each PCR primer. Thermocy-
cling was performed at 95∘C for 15min, followed by 45 cycles
of 94∘C for 20 s, 56∘C for 30 s, and 72∘C for 60 s, followed
by a final extension of 72∘C for 3min. Unincorporated
dNTPs were deactivated using 0.3 units of shrimp alkaline
phosphatase (Clontech Laboratories, Inc., Mountain View,
USA) at 37∘ for 40min and primer extension was carried out
using 7–14𝜇M of each primer extension probe (depending
on the mass), 1 unit of iPLEX termination mix, and 1 unit of
iPLEX enzyme.
Reactions were cycled at 94∘C for 30 s, followed by 44
cycles of 94∘C for 5 s, 5 times (52∘C for 5 s and 80∘C for
5 s). After the addition of a cation exchange resin (Sequenom
Inc.) to remove residual salt from the reactions, 20𝜇L of
water was added and the extension product was spotted onto
a matrix pad (3-hydroxypicoloinic acid) of a SpectroCHIP
(Sequenom Inc.). After analyzing the SpectroCHIPs using a
MALDI-TOF mass spectrometer, spectra were processed by
the SpectroREADER software (Sequenom Inc.) and trans-
ferred to the MassARRAY Typer 4 Analyzer (Sequenom
Inc.) for further analysis. Genotyping for every sample was
performed using the default settings of the MassARRAY
Typer 4 Analyzer. Genotyping calls were generated and were
validated by manual review of the raw mass spectra.
2.3. Microarray Analysis. Microarray analysis was performed
on CRC tumor samples of 688 patients as described previ-
ously [29]. In brief, RNAof sufficient quantity and quality was
extracted from the tumor samples, and gene expressions were
measured on the ALMAC colorectal cancer DSA platform
(Craigavon, Northern Ireland) with a customized Affymetrix
chip with 61,528 probe sets mapping to 15,920 unique Entrez
Gene IDs. Three different probe sets were used to analyze
the expression of FURIN: CB852900 s, NM 002569, and
NM 002569 x.
2.4. Site Directed Mutagenesis. pGL2-P1-SacI construct, here
referred to as pGL2-P1C which contains a DNA fragment,
starting at the Pst1 site in exon 1 and extending to the
Sac1 site 2,6 kb upstream, in the luciferase construct pGL2
has previously been described [16]. This construct contains
part of the human P1 promoter of FURIN containing the C
allele of the SNP −229C/T (rs4932178).TheQuickChange site
directed mutagenesis kit (Stratagene) was used to mutate this
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Figure 1: (a) Kaplan-Meier curve of the postoperational relapse-free survival of CRC according to the patients genotypes of the SNP rs4932178
in the FURIN promoter, C-229T (CC versus CT, 𝑃 = 0.56; CC versus TT, 𝑃 = 0.47). (b) Kaplan-Meier curve of the overall survival of CRC
according to the patients genotypes of the SNP rs4932178 in the FURIN promoter, C-229T (CC versus CT, 𝑃 = 0.57; CC versus TT, 𝑃 = 0.27).
The 𝑃 values in the figure are from the global log-rank test, showing no evidence of a difference between the three groups.
C into a T according to the instructions of the manufacturer,
using the primers: 5󸀠-GGTAAGTGCAGACTCACCCCA-
ATAAATGAGG-3󸀠 and 5󸀠-CCTCATTTATTGGGGTGA-
GTCTGCACTTACC-3󸀠. The resulting construct, referred to
as pGl2-P1T, was sequenced to confirm the mutation.
2.5. Luciferase Assay. 500 ng of the plasmids pGL2-P1C and
pGL2-P1T and pGL2-basic were transfected in HuH7, Caco-
2, and SW480 cells using FuGENE 6 as a transfection reagent
according to the manufacturer’s protocol in 24-well plates.
50 ng/well of pRL-tk (Renilla luciferase expression construct,
Promega) was used for normalization of the transfection
efficiencies. Each construct was transfected at least three
times in triplicate. 24 hours after transfection, cells were lysed
and assayed for luciferase activity using the dual luciferase
assay system (Promega) according to the instructions of the
manufacturer.
2.6. Statistical Analysis. The observed allele frequencies were
tested for Hardy-Weinberg equilibrium and the differences
between the observed and the expected frequencies were
tested for significance using the Chi-square test. Kaplan-
Meier methods were used to estimate the survival proba-
bilities (postoperative relapse-free survival and overall sur-
vival) and the log-rank test was used to assess differences
between patients with the three different SNPs. The associa-
tion between the expression of FURIN and overall survival
was analyzed by Cox regression using continuous FURIN
expression values.The hazard ratio (HR) and the 95%CIwere
determined with the CC allele as reference level.
The unpaired 𝑡-test was used to analyze the data for
the luciferase experiments. The association of the alleles
Table 1: Genotype distribution of SNP rs4932178 (C-229-T) in the
promoter of furin among patients with CRC.
Genotype Number of patients (%)
CC 529 (38.7%)
CT 650 (47.6%)
TT 187 (13.7%)
Total 1366 (100%)
with gene expression levels was done with the Kruskal-
Wallis test. 𝑃 values are two-sided, considered significant
if <0.05 and not adjusted for multiple testing. Statistical
analyses have been performed using R version 2.12.0 or later
(http://www.r-project.org/).
3. Results
SNP rs4932178 was successfully determined for 1366 of the
1382 patients with stage II to stage III adenocarcinoma
in the cohort (Table 1). The distribution frequencies of
the genotypes CC, CT, and TT were 38.7% (529/1366),
47.6% (650/1366), and 13.7% (187/1366), respectively. No
evidence of a violation of the Hardy-Weinberg equilibrium
was found. Further, no statistically significant association
was found between genotypes in clinical and molecular
subgroups (Table 3). Among patients with the different
SNPs in the FURIN promoter, no significant differences in
the relapse-free survival (Figure 1(a)) and the overall sur-
vival (Figure 1(b)) could be observed. CT genotype carriers
showed no differences in relapse-free survival compared to
CC genotype carriers (HR: 1.07, CI: 0.86–1.32, 𝑃 = 0.56) or in
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Figure 2: Luciferase activity of −229C and −229T alleles in the P1
promoter of the Furin gene in three different cell lines: Huh7, Caco-
2, and SW480. Results are shown as fold induction compared to the
luciferase activity in the pGL2-basic vector ± SEM of at least three
independent experiments. No statistically significant differences
could be observed using the Student’s 𝑡-test; 𝑃 = 0.66, 𝑃 = 0.79,
and 𝑃 = 0.69, respectively.
overall survival (HR: 1.08, CI: 0.83–1.39, 𝑃 = 0.57). Likewise,
TT genotype carriers showed no differences in relapse-free
survival compared to CC genotype carriers (HR: 1.12, CI:
0.83–1.52, 𝑃 = 0.47) or in overall survival (HR: 1.22, CI: 0.86–
1.73, 𝑃 = 0.27).
SNP rs4932178 in the promoter of FURIN has been
reported to influence FURIN expression in hepatocellular
carcinoma cell lines [20]. To investigate whether this is
also the case for colon cancer cell lines, the impact of the
two alleles of the SNP on the transcription was analyzed
in the hepatocellular carcinoma cell line Huh7 and in two
colon cancer cell lines Caco-2 and SW480 by luciferase
experiments. In contrast to the previous report, there were no
significant differences in the luciferase activity using pGL2-
P1T or pGL2-P1C constructs in Huh7, Caco-2, and SW480
cells (Figure 2). This suggests that the SNP has no impact on
the FURIN expression in those cell lines.
We subsequently analyzed whether or not the SNP in the
FURIN promoter had an impact on FURIN expression in
the subset of CRC tumor samples of 688 patients for which
gene expression data were also available. Consistent with
the results of the luciferase assay, there were no differences
in the FURIN expression among patients with CC, CT, or
TT genotypes of the SNP using three different probe sets
(Figure 3).
It has been reported that FURIN inhibition in human
colon cancer cell lines inhibits the metastatic potential of
those cell lines [4]. Therefore, we have examined whether
or not FURIN expression by itself is linked with relapse-free
survival in this group of 688 patients with colon cancer. Using
cox regression analysis with continuous FURIN expression
values, no association could be found for FURIN expression
Table 2: Cox regression analysis with continuous furin expression
values showed no association between furin expression and relapse-
free survival for three different probe sets.
Probe set HR CI 𝑃 value
CB852900 s 1.02 0.87–1.20 0.806
NM 002569 0.98 0.77–1.25 0.901
NM 002569 x 0.94 0.72–1.22 0.649
and relapse-free survival for the three different probe sets
(Table 2) (CB852900 s HR: 1.02, CI: 0.87–1.20, 𝑃 = 0.81;
NM 002569 HR: 0.98, CI: 0.77–1.25, 𝑃 = 0.90; NM 002569 x
HR: 0.94, CI: 0.72–1.22, 𝑃 = 0.65). Thus, when the FURIN
expression increases, we found no increased risk for tumor
relapse after the surgery.
4. Discussion
In this paper we show that SNP (C-229T) in the FURIN
promoter is not prognostic to CRC. The distribution pattern
of the CC, CT, and TT genotype carriers was determined in
1366 patients with CRC. This pattern (CC: 38.7%, 529/1366;
CT: 47.6%, 650/1366; TT: 13.7%, 187/1366) was similar to that
of a previous report performed on Swedish patients with
CRC (CC: 34.8%, 104/299; CT: 51.8%, 155/299; and TT: 13.4%,
40/299) (𝑃 = 0.38) [21]. However, the distribution of the
SNP is significantly different in healthy adults from southern
China (CC: 67.9%, 57/84; CT: 26.2%, 22/84; TT: 5.9%, 5/84)
(𝑃 < 0.0001) and in Chinese HBV-infected patients (CC:
61.1%, 374/612; CT: 30.1%, 184/612; TT: 8.8%, 54/612) (𝑃 <
0.0001) [20]. Thus, there are differences in the distribution of
the SNP depending on the ethnic background.
Previously, it has been reported that CT genotype carriers
of a SNP in the FURIN promoter showed a worse survival
than homozygous CC genotype carriers [21]. However, this
was not the case for the rare TT genotype carriers. Therefore,
these results were inconclusive and requested a validation in
a larger group of patients in an independent study. In our
independent study in 1382 patients with CRC, no differences
in overall or relapse-free survival were observed depending
on this SNP. This suggests that the differences in overall
survival observed for theCTgenotype carriers in the previous
report were indeed only a coincidence. Furthermore, the
expression of FURIN in the CRC was also similar in patients
with different SNPs in the FURIN promoter. Consistent with
this observation, no differences in luciferase activity could
be observed in luciferase reporter assays in colon cancer
cell lines after transfection with a construct containing the
C or the T allele of the SNP. This was also not the case
in the hepatocellular carcinoma cell line Huh7. This result
is in contrast to a previous report, where a 3-fold increase
in the transcriptional activity was observed in Huh7 cells
after transfection with a reporter construct containing the T
allele of the SNP compared to one containing the C allele
[20]. The reason why this is the case is not completely
clear but might be due to the different region of the P1
promoter that was used for the luciferase reporter assay.
The construct used in this study contains 2661 bp of the P1
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Figure 3: Boxplot of the gene expression levels of FURIN according to the patient’s genotypes of the SNP rs4932178 in the FURIN promoter,
C-229T, for three different probe sets: (a) CB852900 s, (b) NM 002569, and (c) NM 002569 x. No statistical significant differences could be
observed using the Kruskal-Wallis test; 𝑃 = 0.47, 𝑃 = 0.2, and 𝑃 = 0.33, respectively.
promoter while the construct used by Lei and coworkers
contained only 1268 bp of the P1 promoter (Figure 4) [16, 20].
Since FURIN expression in the HBV-infected patients has
not been investigated directly, it is unclear whether or not
the increased expression in vitro, as observed by Wei and
coworkers, is a reflection of the expression in vivo. Since our
in vitro results are consistent with the in vivo expression data,
it is tempting to speculate that the larger fragment of the P1
promoter contains additional elements relevant for FURIN
expression. The most proximal region of the P1 promoter,
which contains the TATA box and which is included in
both constructs, contains most of the elements required for
constitutive promoter function [16]. Nevertheless, it fails to
respond significantly to TGF𝛽1 stimulation [18]. The 809 bp
region between positions −1317 and −508 carries most of
the transcriptional activation of the FURIN P1 promoter by
TGF𝛽1. This can be explained by the presence of multiple
putative activin responsive elements (ARE) and a Smad
binding element (SBE) in this region. It should be noted
that the SBE is only present in our construct but not in the
construct used by Lei and coworkers. Likewise, several other
putative ARE binding sites and SBE binding sites are located
upstream of the −1253 position and are only included in
the construct used in this study (Figure 4). The presence of
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Table 3: Distribution of genotypes across clinical and molecular subgroups.
Characteristic CC (𝑛 = 502): 𝑛 (%) CT (𝑛 = 613): 𝑛 (%) TT (𝑛 = 179): 𝑛 (%) 𝑃
Stage
2 172 (34.3%) 177 (28.9%) 52 (29.1%) 0.13144
3 330 (65.7%) 436 (71.1%) 127 (70.9%)
nstage
N0 172 (34.3%) 177 (28.9%) 52 (29.1%)
0.17465N1 226 (45.0%) 276 (45.0%) 82 (45.8%)
N2 104 (20.7%) 160 (26.1%) 45 (25.1%)
tstage
T12 27 (5.4%) 33 (5.4%) 14 (7.8%)
0.5306T3 385 (76.7%) 480 (78.3%) 130 (72.6%)
T4 90 (17.9%) 100 (16.3%) 35 (19.6%)
Grade
G-12 444 (89.3%) 556 (91.1%) 165 (92.7%) 0.37509
G-34 53 (10.7%) 54 (8.9%) 13 (7.3%)
Tumor site
Left 298 (59.4%) 370 (60.4%) 109 (60.9%) 0.92295
Right 204 (40.6%) 243 (39.6%) 70 (39.1%)
MSI
MSS 407 (85.0%) 494 (85.5%) 137 (82.0%) 0.54428
MSI-H 72 (15.0%) 84 (14.5%) 30 (18.0%)
BRAF
wt 458 (92.5%) 563 (93.1%) 156 (88.6%) 0.15503
mut 37 (7.5%) 42 (6.9%) 20 (11.4%)
loh18q.2inf
No LOH 111 (34.8%) 120 (30.7%) 30 (28.6%) 0.37806
LOH 208 (65.2%) 271 (69.3%) 75 (71.4%)
TS
75 153 (33.6%) 192 (34.3%) 55 (33.3%) 0.96312
25/50 302 (66.4%) 367 (65.7%) 110 (66.7%)
SMAD4
No loss 400 (81.5%) 469 (77.3%) 140 (78.7%) 0.23089
Any loss 91 (18.5%) 138 (22.7%) 38 (21.3%)
KRAS
wt 303 (61.2%) 358 (59.5%) 111 (64.5%) 0.47866
mut 192 (38.8%) 244 (40.5%) 61 (35.5%)
those additional elements relevant for FURIN expression can
thus explain the differences observed by Lei and coworkers.
In any case, it is clear that differences in this SNP in the
P1 promoter of FURIN do not affect FURIN expression in
CRC and that this SNP has no predictive outcome in this
tumor type. Likewise, also in human atherosclerotic plaques
the SNP C-229T was not found to be associated with FURIN
expression [30].
We have also studied whether or not FURIN expression
by itself has a predictive outcome in colon cancer. Indeed,
FURIN inhibition in human colorectal tumor cells repressed
tumor metastases via inhibition of IGF1R processing in
mouse models [4]. Therefore, we investigated the associa-
tion between FURIN expression and relapse-free survival
in patients with CRC but not stratified for IGF1R pathway
activation. No association could be found. Although this
might suggest that FURIN inhibition is of limited value for
patients with CRC, it may also be that the expression of
FURIN in all tumors is sufficiently high not to be limiting in
the processing of substrates. It the latter case, it remains well
possible that inhibition below a certain threshold will provide
therapeutic benefit.
In contrast to patients with CRCwhere decreased FURIN
expression levels do not influence relapse-free survival, we
previously demonstrated in a mouse model for pleomorphic
adenomas of the salivary glands that even monoallelic
deletion of Furin resulted in a significant delay in the tumor
formation [2]. Thus, the benefit of decreased FURIN levels
depends on the particular tumor type. In hepatocellular
carcinoma patients, high FURIN expression even predicts
a better postoperative disease-free survival [31]. In line
with this result, FURIN overexpression in hepatocellular
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Figure 4: Schematic representation of the three different Furin promoters (P1, P1A, and P1B), the pGL2-P1C construct used in this study, and
the construct used by Lei and coworkers.The positions are determined from the mRNA sequence, GenBank accession number: NM 002569.
Elements important for FURIN expression are indicated. ARE = activin responsive element; SBE = smad binding elements; HBS = HIF-1
consensus binding sequence; GRS = Gata-1 recognition sequence.
carcinoma cell lines significantly suppressed the tumor
growth in subcutaneous xenograft experiments compared to
themock control.Thus, depending on the cancer type FURIN
inhibition is either beneficial (salivary gland tumors [2], skin
cancer [3]) or disadvantageous (hepatocellular carcinoma
[31]) or has no clear effect (CRC) on the tumorigenic process.
5. Conclusions
In this report, we demonstrate that a SNP in the P1 promoter
of FURIN does not influence its expression levels in CRC
and has no impact on the postoperative disease-free survival
and overall survival. Furthermore, FURIN expression levels
have no impact on the postoperative disease-free survival in
CRC. This is in contrast to other tumor types either where
FURIN expression predicts a better postoperative disease-
free survival such as in hepatocellular carcinoma or where
FURIN inhibition can delay the tumorigenic process (salivary
gland tumors, skin cancer). This demonstrates that the role
of FURIN in tumorigenesis depends on the particular tumor
type and the affected signaling pathways.
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